Advertisement

Der Onkologe

, Volume 25, Issue 2, pp 159–164 | Cite as

Integrative Medizin bei Patientinnen mit Ovarialkarzinomen

Integrative Medizin bei Ovarialkarzinom
  • Karsten MünstedtEmail author
  • Birthe Osorio
Integrative Medizin
  • 47 Downloads

Zusammenfassung

Hintergrund

Unter integrativer Medizin versteht man die Kombination von Methoden der konventionellen Medizin mit anderen Methoden, die primär dem Umfeld der komplementären und alternativen Medizin entstammen und sich in Studien nachweislich als sinnvoll erwiesen haben.

Ziel

Dieser Beitrag versucht die Frage zu beantworten, ob und ggf. welche Methoden sinnvoll mit den Strategien der konventionellen Medizin bei Patientinnen mit Ovarialkarzinom kombiniert werden können.

Ergebnisse

Unter Berücksichtigung der Aspekte Effektivität, Sicherheit, Kosten und Verfügbarkeit finden sich z. T. aus Metaanalysen stammende Daten, die zeigen, dass sich das Management der Behandlung des Ovarialkarzinoms im Hinblick auf supportive Maßnahmen begleitend zu OP und Chemotherapie verbessern lässt. Kaugummikauen führt dazu, dass die Darmtätigkeit früher wiederhergestellt wird, Eiswürfellutschen und Honig können eine chemotherapieinduzierte Mukositis verringern, um nur einige Beispiele zu nennen. Ergänzende Maßnahmen, die die Prognose des Ovarialkarzinoms verbessern würden, sind weniger gut erforscht.

Schlussfolgerung

Wenngleich bislang keine Behandlungskonzepte offiziell als integrativ gelten dürfen, so gibt es doch Ansätze, die sinnvoll die Behandlung bei Patientinnen mit Ovarialkarzinom ergänzen können. Hinweise, dass alternative oder esoterische Therapiekonzepte sinnvoll sein könnten, finden sich nicht.

Schlüsselwörter

Chemotherapie Komplementärmedizin Alternativmedizin Ovarielle Tumoren Supportive Medizin 

Integrative medicine for patients with ovarian cancer

Integrative medicine and ovarian cancer

Abstract

Background

Integrative medicine is considered to be a combination of methods from conventional medicine and other methods, which primarily originate from the fields of complementary and alternative medicine and have been proven to be efficacious in rigorous trials.

Aim

This article tries to answer the question whether there are methods which have been studied well enough so they can be reasonably combined with conventional medicine in patients with ovarian cancer.

Results

Considering the factors efficacy, safety, costs and availability, data partially originating from meta-analyses are available, which show that management of the treatment of ovarian cancer may be improved by supportive measures during surgery and chemotherapy. For example, chewing gum improves gastrointestinal function after gynecological surgery and oral cryotherapy (sucking ice cubes) and honey can have beneficial effects on oral mucositis induced by chemotherapy, to name but a few. Complementary methods which might improve patients’ prognosis have so far been less well studied.

Conclusion

Although no treatment concepts can be officially considered to be integrative, there are approaches which can reasonably supplement the treatment of ovarian cancer patients. There is no evidence that alternative or esoteric treatment concepts could be beneficial.

Keywords

Chemotherapy Complementary medicine Alternative medicine Ovarian neoplasms Supportive care 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

K. Münstedt und B. Osorio geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    Bittenbring JT, Neumann F, Altmann B, Achenbach M, Reichrath J, Ziepert M, Geisel J, Regitz E, Held G, Pfreundschuh M (2014) Vitamin d deficiency impairs rituximab-mediated cellular cytotoxicity and outcome of patients with diffuse large B‑cell lymphoma treated with but not without rituximab. J Clin Oncol 32:3242–3248CrossRefGoogle Scholar
  2. 2.
    Braun L, Harris J, Katris P, Cain M, Dhillon H, Koczwara B, Olver I, Robotin M (2014) Clinical Oncology Society of Australia position statement on the use of complementary and alternative medicine by cancer patients. Asia Pac J Clin Oncol 10:289–296CrossRefGoogle Scholar
  3. 3.
    Buller RE, Skilling JS, Sood AK, Plaxe S, Baergen RN, Lager DJ (1998) Field cancerization: why late “recurrent” ovarian cancer is not recurrent. Am J Obstet Gynecol 178(4):641–649CrossRefGoogle Scholar
  4. 4.
    Chan KK, Yao TJ, Jones B, Zhao JF, Ma FK, Leung CY, Lau SK, Yip MW, Ngan HY (2011) The use of Chinese herbal medicine to improve quality of life in women undergoing chemotherapy for ovarian cancer: a double-blind placebo-controlled randomized trial with immunological monitoring. Ann Oncol 22:2241–2249CrossRefGoogle Scholar
  5. 5.
    Chang WP, Peng YX (2018) Does the oral administration of ginger reduce chemotherapy-induced nausea and vomiting?: a meta-analysis of 10 randomized controlled trials. Cancer Nurs.  https://doi.org/10.1097/NCC.0000000000000648 CrossRefPubMedGoogle Scholar
  6. 6.
    Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (2017) S3-Leitlinie Maligne Ovarialtumoren. https://www.awmf.org/uploads/tx_szleitlinien/032-035-OLl_Ovarialkarzinom_2017-11.pdf. Zugegriffen: 16.11.2018
  7. 7.
    Evans SO, Khairuddin PF, Jameson MB (2017) Optimising selenium for modulation of cancer treatments. Anticancer Res 37:6497–6509PubMedGoogle Scholar
  8. 8.
    Fink M (2011) Vitamin D deficiency is a cofactor of chemotherapy-induced mucocutaneous toxicity and dysgeusia. J Clin Oncol 29:e81–e82CrossRefGoogle Scholar
  9. 9.
    Friend A, Rubagumya F, Cartledge P (2018) Global Health Journal Club: is honey effective as a treatment for chemotherapy-induced mucositis in paediatric oncology patients? J Trop Pediatr 64:162–168CrossRefGoogle Scholar
  10. 10.
    Grossarth-Maticek R, Ziegler R (2007) Prospective controlled cohort studies on long-term therapy of ovairian cancer patients with mistletoe (Viscum album L.) extracts iscador. Arzneimittelforschung 57:665–678PubMedGoogle Scholar
  11. 11.
    Guo H, Guo J, Xie W, Yuan L, Sheng X (2018) The role of vitamin D in ovarian cancer: epidemiology, molecular mechanism and prevention. J Ovarian Res 11:71CrossRefGoogle Scholar
  12. 12.
    He M, Zhang B, Shen N, Wu N, Sun J (2018) A systematic review and meta-analysis of the effect of low-level laser therapy (LLLT) on chemotherapy-induced oral mucositis in pediatric and young patients. Eur J Pediatr 177:7–17CrossRefGoogle Scholar
  13. 13.
    Johnson SB, Park HS, Gross CP, Yu JB (2018) Use of alternative medicine for cancer and its impact on survival. J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx145 CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Judson PL, Dickson EL, Argenta PA, Xiong Y, Geller MA, Carson LF, Ghebre R, Jonson AL, Downs LS Jr. (2011) A prospective, randomized trial of integrative medicine for women with ovarian cancer. Gynecol Oncol 123:346–350CrossRefGoogle Scholar
  15. 15.
    Kalogera E, Nelson G, Liu J, Hu QL, Ko CY, Wick E, Dowdy SC (2018) Surgical technical evidence review for gynecologic surgery conducted for the Agency for Healthcare Research and Quality Safety Program for Improving Surgical Care and Recovery. Am J Obstet Gynecol.  https://doi.org/10.1016/j.ajog.2018.07.014 CrossRefPubMedGoogle Scholar
  16. 16.
    Li B, Bu S, Sun J, Guo Y, Lai D (2018) Artemisinin derivatives inhibit epithelial ovarian cancer cells via autophagy-mediated cell cycle arrest. Acta Biochim Biophys Sin (Shanghai).  https://doi.org/10.1093/abbs/gmy125 CrossRefGoogle Scholar
  17. 17.
    Lyman GH, Greenlee H, Bohlke K, Bao T, DeMichele AM, Deng GE, Fouladbakhsh JM, Gil B, Hershman DL, Mansfield S, Mussallem DM, Mustian KM, Price E, Rafte S, Cohen L (2018) Integrative therapies during and after breast cancer treatment: ASCO endorsement of the SIO clinical practice guideline. J Clin Oncol 36:2647–2655CrossRefGoogle Scholar
  18. 18.
    Miao J, Liu X, Wu C, Kong H, Xie W, Liu K (2017) Effects of acupressure on chemotherapy-induced nausea and vomiting—a systematic review with meta-analyses and trial sequential analysis of randomized controlled trials. Int J Nurs Stud 70:27–37CrossRefGoogle Scholar
  19. 19.
    Münstedt K (2018) Integrative Onkologie – was sind die Fakten? Tumordiagn Ther 39:441–444CrossRefGoogle Scholar
  20. 20.
    Mutluay Yayla E, Izgu N, Ozdemir L, Aslan Erdem S, Kartal M (2016) Sage tea-thyme-peppermint hydrosol oral rinse reduces chemotherapy-induced oral mucositis: a randomized controlled pilot study. Complement Ther Med 27:58–64CrossRefGoogle Scholar
  21. 21.
    Pelzer F, Tröger W, Nat DR (2018) Complementary treatment with mistletoe extracts during chemotherapy: safety, neutropenia, fever, and quality of life assessed in a randomized study. J Altern Complement Med 24:954–961CrossRefGoogle Scholar
  22. 22.
    Pistollato F, Calderón Iglesias R, Ruiz R, Aparicio S, Crespo J, Dzul Lopez L, Giampieri F, Battino M (2017) The use of natural compounds for the targeting and chemoprevention of ovarian cancer. Cancer Lett 411:191–200CrossRefGoogle Scholar
  23. 23.
    Playdon MC, Nagle CM, Ibiebele TI, Ferrucci LM, Protani MM, Carter J, Hyde SE, Neesham D, Nicklin JL, Mayne ST, Webb PM (2017) Pre-diagnosis diet and survival after a diagnosis of ovarian cancer. Br J Cancer 116:1627–1637CrossRefGoogle Scholar
  24. 24.
    Tang J, Zheng JS, Fang L, Jin Y, Cai W, Li D (2015) Tea consumption and mortality of all cancers, CVD and all causes: a meta-analysis of eighteen prospective cohort studies. Br J Nutr 114:673–683CrossRefGoogle Scholar
  25. 25.
    Tavakoli Ardakani M, Ghassemi S, Mehdizadeh M, Mojab F, Salamzadeh J, Ghassemi S, Hajifathali A (2016) Evaluating the effect of Matricaria recutita and Mentha piperita herbal mouthwash on management of oral mucositis in patients undergoing hematopoietic stem cell transplantation: a randomized, double blind, placebo controlled clinical trial. Complement Ther Med 29:29–34CrossRefGoogle Scholar
  26. 26.
    Wang L, Gu Z, Zhai R, Zhao S, Luo L, Li D, Zhao X, Wei H, Pang Z, Wang L, Liu D, Wang Q, Gao C (2015) Efficacy of oral cryotherapy on oral mucositis prevention in patients with hematological malignancies undergoing hematopoietic stem cell transplantation: a meta-analysis of randomized controlled trials. PLoS ONE 10:e128763CrossRefGoogle Scholar
  27. 27.
    Wei Y, Pu X, Zhao L (2017) Preclinical studies for the combination of paclitaxel and curcumin in cancer therapy. Oncol Rep 37:3159–3166 (Review)CrossRefGoogle Scholar
  28. 28.
    Xu C, Peng J, Liu S, Qi DY (2018) Effect of chewing gum on gastrointestinal function after gynecological surgery: a systematic literature review and meta-analysis. J Obstet Gynaecol Res 44:936–943CrossRefGoogle Scholar
  29. 29.
    Zeichner SB, Koru-Sengul T, Shah N, Liu Q, Markward NJ, Montero AJ, Glück S, Silva O, Ahn ER (2014) Improved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clin Breast Cancer.  https://doi.org/10.1016/j.clbc.2014.08.001 CrossRefPubMedGoogle Scholar
  30. 30.
    Zhan X, Wang J, Pan S, Lu C (2017) Tea consumption and the risk of ovarian cancer: a meta-analysis of epidemiological studies. Oncotarget 8:37796–37806PubMedPubMedCentralGoogle Scholar
  31. 31.
    Zhang M, Lee AH, Binns CW, Xie X (2004) Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 112:465–469CrossRefGoogle Scholar
  32. 32.
    Zhou Y, Cartmel B, Gottlieb L, Ercolano EA, Li F, Harrigan M, McCorkle R, Ligibel JA, von Gruenigen VE, Gogoi R, Schwartz PE, Risch HA, Irwin ML (2017) Randomized trial of exercise on quality of life in women with ovarian cancer: women’s activity and lifestyle study in Connecticut (WALC). J Natl Cancer Inst.  https://doi.org/10.1093/jnci/djx072 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2018

Authors and Affiliations

  1. 1.FrauenklinikOrtenau-Klinikum Offenburg-GengenbachOffenburgDeutschland

Personalised recommendations